文献速递主动脉疾病

复杂腹主动脉及胸腹主动脉瘤开窗分支腔内修复术的连续结局

Outcomes of fenestrated and branched endovascular repair of complex abdominal and thoracoabdominal aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2017-03-01

单中心前瞻性观察队列研究连续纳入100例复杂主动脉瘤患者,采用开窗或分支腔内修复术,30天死亡率为3%,1年生存率87%,免于I/III型内漏97%,靶血管通畅率92%,免于破裂100%。

要点

  • 复杂主动脉瘤可行开窗/分支腔内修复,30天死亡率3%。
  • 1年生存率87%,免于I/III型内漏97%。
  • 靶血管通畅率92%,免于主动脉破裂100%。

核心结论

  • 复杂主动脉瘤现在可以通过微创开窗和分支腔内修复术治疗。
  • 腔内技术可能在复杂主动脉瘤疾病管理中发挥越来越重要的作用。

研究设计与样本

  • 单中心、前瞻性、观察性队列研究,评估连续接受开窗或分支腔内修复的复杂主动脉瘤患者的30天和1年结局。

主要发现

  • 治疗动脉瘤包括4例(4%)髂总、42例(42%)近肾、18例(18%)肾旁和36例(36%)胸腹主动脉瘤。
  • 修复包括309个开窗、分支和扇形(平均每例3.1支分支动脉)。
  • 30天事件率:死亡3例(3%),靶动脉闭塞6例(6%),进展至透析5例(5%),入路并发症8例(8%),下肢轻瘫1例(1%),肠缺血1例(1%),无心肌梗死、瘫痪或卒中。
  • 10例I型或III型内漏中8例解决(7例经二次干预,1例未干预)。
  • 1年Kaplan-Meier分析:生存率87%,免于I型或III型内漏97%,靶血管通畅率92%,免于主动脉破裂100%。

临床怎么用

  • 对于复杂主动脉瘤,开窗和分支腔内修复术可作为微创治疗选择。
  • 需关注30天内靶动脉闭塞、透析进展和入路并发症。
  • 术后需监测I/III型内漏并及时处理。

局限性

  • 单中心研究,样本量100例。
  • 平均随访563天(四分位距156-862),3例(3%)失访。
  • 部分数据来自医生赞助的研究性器械豁免临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: More than 80% of infrarenal aortic aneurysms are treated by endovascular repair. However, adoption of fenestrated and branched endovascular repair for complex aortic aneurysms has been limited, despite high morbidity and mortality associated with open repair. There are few published reports of consecutive outcomes, inclusive of all fenestrated and branched endovascular repairs, starting from the inception of a complex aortic aneurysm program. Therefore, we examined a single center's consecutive experience of fenestrated and branched endovascular repair of complex aortic aneurysms. METHODS: This is a single-center, prospective, observational cohort study evaluating 30-day and 1-year outcomes in all consecutive patients who underwent fenestrated and branched endovascular repair of complex aortic aneurysms (definition: requiring one or more fenestrations or branches). Data were collected prospectively through an Institutional Review Board-approved registry and a physician-sponsored investigational device exemption clinical trial (G130210). RESULTS: We performed 100 consecutive complex endovascular aortic aneurysm repairs (November 2010 to March 2016) using 58 (58%) commercially manufactured custom-made devices and 42 (42%) physician-modified devices to treat 4 (4%) common iliac, 42 (42%) juxtarenal, 18 (18%) pararenal, and 36 (36%) thoracoabdominal aneurysms (type I, n = 1; type II, n = 4; type III, n = 12; type IV, n = 18; arch, n = 1). The repairs included 309 fenestrations, branches, and scallops (average of 3.1 branch arteries/case). All patients had 30-day follow-up for 30-day event rates: three (3%) deaths; six (6%) target artery occlusions; five (5%) progressions to dialysis; eight (8%) access complications; one (1%) paraparesis; one (1%) bowel ischemia; and no instances of myocardial infarction, paralysis, or stroke. Of 10 type I or type III endoleaks, 8 resolved (7 with secondary intervention, 1 without intervention). Mean follow-up time was 563 days (interquartile range, 156-862), with three (3%) patients lost to follow-up. On 1-year Kaplan-Meier analysis, survival was 87%, freedom from type I or type III endoleak was 97%, target vessel patency was 92%, and freedom from aortic rupture was 100%. Average lengths of intensive care unit stay and inpatient stay were 1.4 days (standard deviation, 3.3) and 3.6 days (standard deviation, 3.6), respectively. CONCLUSIONS: These results show that complex aortic aneurysms can now be treated with minimally invasive fenestrated and branched endovascular repair. Endovascular technologies will likely continue to play an increasingly important role in the management of patients with complex aortic aneurysm disease.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Schanzer A, Simons JP, Flahive J, et al. Outcomes of fenestrated and branched endovascular repair of complex abdominal and thoracoabdominal aortic aneurysms. J Vasc Surg. 2017. PMID: 28259577. doi:10.1016/j.jvs.2016.12.111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。